Abstract 48P
Background
Sentinel lymph node biopsy (SLNB) in post-neoadjuvant chemotherapy (NACT) has demonstrated a higher false negative rate (FNR) compared to early breast cancer. This might result from a non-uniform pattern of tumour regression in SLN and Non-SLN within the axilla. SLNB can assess SLN alone by itself, but preoperative axillary ultrasound (AUS) can also determine the characteristics of Non-SLN. We studied whether axillary staging in post-NACT patients could be improved by combining AUS and SLNB to reduce false negative cases.
Methods
It was a single-centre, prospective study that was conducted between September 2020 and June 2022. All Post-NACT, clinically node-negative(cN0) patients who were scheduled for surgery were enrolled and underwent AUS. AUS normal node patients underwent SLNB using fluorescein and methylene blue followed by Axillary Lymph Node Dissection (ALND). We evaluated the AUS's Positive Predictive Value (PPV), Negative Predictive Value (NPV) and FNR in cN0 patients. The FNR of SLNB was calculated in patients who had cN0 and AUS normal nodes.
Results
cN0 was found in 62 patients out of 136 post-NACT patients.AUS had PPV and NPV of 90.6% and 76.6%, respectively. The FNR for AUS alone was 19.4% (7/36). Loss of fatty hilum was found to have a PPV of 89.3% and a sensitivity of 70%, making it the most reliable marker of nodal metastasis. Methylene blue allergy was observed in 1 patient. The FNR of SLNB was 8.6% (2/23) for the patients who had been selected for SLNB based on AUS normal nodes.
Conclusions
AUS alone or SLNB alone is insufficient to determine axilla node-negative status and can't omit ALND because each has a high FNR (>10%). If AUS findings are considered for selecting patients for SLNB, it reduces its FNR to below 10% and improves the accuracy of axillary staging in post-NACT patients.
Clinical trial identification
Clinical Trials Registry (India) number- CTRI/2020/10/028337.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract
352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Presenter: Tomotaka Suzuki
Session: Poster Display
Resources:
Abstract